We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About Chesson Laboratory Associates Stock

Invest in or calculate the value of your shares in Chesson Laboratory Associates or other pre-IPO companies through EquityZen's platform.

Get Started

Chesson Laboratory Associates Stock (CLBA)

Chesson Laboratory Associates is a healthcare products company developing polymer-based medical care products in the United States.

About Chesson Laboratory Associates Stock

Founded

2006

Headquarters

Durham, NC, US

Total Funding

2.0M

Industries

Science and Engineering, Health Care, Biotechnology

Chesson Laboratory Associates, Inc., a healthcare products company, develops and delivers polymer-based medical care products in the United States. It offers Nuvaderm, a liquid bandage product; Nuvavet, an animal healthcare bandage; and LIQUICURE, a biocompatible topical onychomycosis treatment. The company’s products are used by medical professionals and consumers, as well as medics and personnel in armed forces. It offers products in North Carolina, South Carolina, and Virginia through Mutual Drug outlets. Chesson Laboratory Associates, Inc. was founded in 2006 and is based in Durham, North Carolina.

Chesson Laboratory Associates Management

Leadership team at Chesson Laboratory Associates

Vice President of Corporate Development

J. Houston Barnes

Chief Executive Officer

Scott E. Neuville

Locked Features

Join now and verify your accreditation status to gain access to:

  • Chesson Laboratory Associates current valuation
  • Chesson Laboratory Associates stock price
  • Available deals in Chesson Laboratory Associates and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in Chesson Laboratory Associates stock?

Accredited investors can buy pre-IPO stock in companies like Chesson Laboratory Associates through EquityZen funds. These investments are made available by existing Chesson Laboratory Associates shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell Chesson Laboratory Associates stock?

Shareholders can sell their Chesson Laboratory Associates stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."